An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Preclinical Safety and Efficacy Data Using CampbellCell™ for Treatment of Schizophrenia
Therapeutic Solutions International announced positive preclinical efficacy and safety data for its CampbellCell™ allogeneic primed mesenchymal stem cell therapy, targeting schizophrenia. The company previously filed a substantial patent covering stem cell approaches for treating schizophrenia in September 2020. Collaborations with Campbell Neurosciences have led to significant advancements, including recruiting industry experts and establishing a blood-based marker for suicidal tendencies. The development may represent a breakthrough in treating mental health disorders that often rely on invasive methods.
Positive
Positive preclinical efficacy and safety data for CampbellCell™.
Significant patent application filed covering over 1000 claims for schizophrenia treatment.
Collaboration with Campbell Neurosciences leading to expert recruitment and advancements in treatment.
Negative
None.
Suicide Prevention Company Leverages Cell Therapy Expertise of Therapeutic Solutions International and Allogen Biologics to Advance First Cell Therapy Product Towards Clinical Trials
OCEANSIDE, Calif.--(BUSINESS WIRE)--
Therapeutic Solutions International announced today positive preclinical efficacy and safety data using its newly announced CampbellCell™ allogeneic primed mesenchymal stem cell.
In September 2020, Therapeutic Solutions International filed a landmark patent application with over 1000 claims covering novel stem cell-based approaches to treating schizophrenia1. In June 2021, Campbell Neurosciences, together with Therapeutic Solutions International reported deficiencies in T regulatory cells in schizophrenia2, which could be repaired by administration of tolerogenic dendritic cells3. The CampbellCell, which is described in the patent application is specially generated to induce generation of tolerogenic dendritic cells in vitro and in vivo.
“We are extremely excited about our ongoing work with Therapeutic Solutions International, and their esteemed collaborators and advisors, which has resulted in the first stem cell therapy candidate for certain subsets of schizophrenia,” said Kalina O’Connor, President and CEO of Campbell Neurosciences. “The current lack of progress in mental illness in general, and specifically in schizophrenia, is demonstrated by the continued utilization of highly invasive methods such as electroconvulsive therapy. Through our work, we aim to develop new treatments that attack this program at its core and not simply cover up symptoms.”
“Allogen Biologics, as a subsidiary of Therapeutic Solutions International is pleased to have worked on developing, optimizing and standardizing production of the CampbellCell™ product,” said Dr. Thomas Ichim, President and CEO of Allogen and Board Member of Therapeutic Solutions International. “We are optimistic that this is the first of numerous cell products that we will be developing in the interest of combining neurosciences and regenerative medicine.”
“We at Therapeutic Solutions International are excited to see the progress made by Campbell Neurosciences,” said Timothy Dixon, President and CEO of the Company and co-inventor of the CampbellCell. “Milestones achieved by Ms. O’Connor and her team at Campbell included recruiting international opinion leaders such as Dr. Peter Farrell Chairman of the 35 billion market cap company Resmed4, establishing the first blood-based marker of suicidal tendencies5, and now progressing with preclinical development for the first cell-based therapy for schizophrenia. We are proud of the contributions that Campbell Neurosciences has made to the field of mental illness and look forward to continuing progress in this important field.”
CampbellCell™ is an allogeneic primed mesenchymal stem cell therapy targeting schizophrenia.
What recent data has TSOI released regarding CampbellCell™?
TSOI has announced positive preclinical efficacy and safety data for CampbellCell™.
What are the implications of TSOI's recent patent application?
The patent covers novel stem cell-based approaches for treating schizophrenia, potentially leading to significant advancements in mental health therapy.
What partnerships are involved in TSOI's CampbellCell™ development?
TSOI is collaborating with Campbell Neurosciences and Allogen Biologics to advance CampbellCell™ towards clinical trials.
How might CampbellCell™ impact schizophrenia treatment?
CampbellCell™ aims to provide a new treatment option that directly addresses the underlying issues of schizophrenia rather than just alleviating symptoms.
